Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cryptosporidium parvum surface antigens are a diverse group of proteins and glycoproteins expressed on the external membranes of the parasite during its various life stages, including oocysts, sporozoites, and merozoites. Key antigens such as the GP60 (gp40/15) complex, P23 (Cp23), and the thrombospondin-related anonymous protein (TRAP) are essential for the parasite's ability to excyst, move via gliding motility, and adhere to or invade host intestinal epithelial cells (Bouzid et al., 2013; O'Connor et al., 2007). These antigens are the primary targets for the host's humoral and cellular immune responses and are central to the pathogenesis of cryptosporidiosis, a significant cause of severe diarrheal disease worldwide, particularly in children and immunocompromised individuals (Checkley et al., 2015). While current small-molecule treatments like nitazoxanide target internal metabolic enzymes rather than surface proteins, these antigens are the focus of intensive research for passive immunotherapy and vaccine development. Experimental approaches using monoclonal antibodies and hyperimmune bovine colostrum aim to neutralize these antigens to prevent infection and reduce the severity of clinical symptoms (Hunt et al., 2002; Perryman et al., 1999).
Neutralization of sporozoites and merozoites to prevent attachment and invasion of host intestinal epithelial cells, thereby interrupting the parasite life cycle.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cryptosporidium parvum surface antigens (C. parvum surface antigens).